No results for ‘’
Windlas Biotech Ltd
NSE: WINDLAS BSE: 543329
₹829.45
(0.71%)
Wed, 17 Jun 2026, 02:27 am
Market Cap (in Cr)1719.2
PE Ratio26.52
Dividend0.71
Health Technology
Pharmaceuticals: Major
24.5KCompany History
2001
- The Company was incorporated as Windlas Biotech Limited.
- The Company received the certificate for commencement of business.
- The Company commenced operations at Dehradun Plant – I and initiated commercial production.
2009
- The Registered Office of the Company was shifted from the state of Delhi to the state of Uttarakhand.
- The Company commenced operations at Dehradun Plant – IV.
2010
- The alteration with respect to the place of the Registered Office was confirmed by the order of the Company Law Board, New Delhi.
- Revenues crossed Rs. 1,000 million for the FY 2009-10.
2011
- A fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand.
2014
- The Company received its first USFDA inspection clearance for the WHC Plant.
- Revenues crossed Rs. 2,000 million for the FY 2013-14.
- The Company commenced operations at Dehradun Plant – II.
2015
- The Company received an investment of Rs. 750 million from Tano India Private Equity Fund II.
2016
- The Company was converted into a private limited company.
- A fresh certificate of incorporation consequent upon conversion and change of name to Windlas Biotech Private Limited was granted.
2017
- Revenues crossed Rs. 3,000 million for the FY 2016-17.
2018
- The Company launched its first product in the United States from Dehradun Plant – IV.
- The Company commenced operations at Dehradun Plant – III.
2021
- The Company was converted from a private limited company to a public limited company.
- The name of the Company was changed to Windlas Biotech Limited.
- A fresh certificate of incorporation was granted by the RoC.
- Approval of Scheme of Amalgamation of the erstwhile subsidiary, Windlas Healthcare, with and into the Company was obtained.
2022
- The Company received a certificate of Good Manufacturing Practices (GMP) from SAHPRA.